Apollo Hospitals Enterprise Ltd

- Platform GMV growth guidance: Around 30-35% year-on-year for the full year FY '26, excluding IP/OP GMV. - Hospital business revenue growth: Existing hospitals expected to grow at 12-14%, with additional beds adding another 3-4%. - Pharmacy physical stores: Targeting ~600 new store additions per year, with same-store growth at about 16-18%, driven by private label and store refresh initiatives. - Digital business (online pharmacy): GMV growing at about 30%, with an expected trajectory of 20-22% annual growth to reach INR62 billion by Q4 FY '27. - Margin expansion: Existing hospital business expected to improve margins by at least 100 basis points next year despite INR150 crore losses from new units. - Overall volume growth focus: Targeting a mix of volume increase and case mix/pricing improvements to drive ARPP growth of ~5%.

- Platform GMV is expected to grow around 30% this financial year and about 30% next year excluding IP/OP contributions. - Hospital business aims for 12-14% revenue growth on existing hospitals with an additional 3-4% from new beds next year. - Hospital margins in the existing network can expand by at least 100 basis points next year despite INR150 crore losses from new units. - New hospitals operationalizing 50% of 1,500 beds next year; break-even on ~1,300 beds expected in 2 years. - Digital business (Apollo 24/7 and pharmacy) targeting about 25% growth over next five quarters, with online pharmacy showing 30%+ GMV growth. - EBITDA losses from new hospitals are expected but mitigated by improved asset utilization and cost control in existing network. - Overall margin expansion and revenue growth poised to maintain strong profitability trajectory over coming years.

The provided transcript from the Apollo Hospitals Limited conference call does not contain explicit information regarding the company's current or expected order book or pending orders. The discussion primarily centers around operational aspects such as hospital bed capacity expansion, occupancy rates, margin trajectories, revenue growth, and digital business performance. There is no mention of order book status or pending contracts. If you require specifics on order book or pending orders, please provide additional sections or documents that may cover this information.

- There is no specific mention of any current or future fundraising through debt or equity in the provided transcript on page 18 or the surrounding pages. - The management discussed operational expansion, new beds, revenue growth, and margin guidance but did not indicate plans for raising capital through equity or debt. - The focus appears to be on phased capacity operationalization, improving profitability, and disciplined execution rather than fundraising activities. - Any material update on fundraising, if planned, might be communicated in future disclosures or earnings calls beyond the current transcript.

- 1,500 new hospital beds to be added over the next year, with 50% (750 beds) operationalized in the coming year and the remaining 750 beds thereafter. - Breakeven expected on 1,300 new beds within 2 years. - Operationalization phased: 40-50% of beds expected to be operationalized by Q1, including facilities in Calcutta, Hyderabad, Pune, Sarjapur; Gurugram beds expected by Q2 due to delays. - Capital investment focused on phased capacity operationalization and opening new beds in Healthcare Services. - Continued investments in clinical excellence, technology, and market share expansion. - No specific quantification of total capex provided but strategic focus on expansion and technology adoption to drive growth and profitability.